Johnson & Johnson is at the forefront of medical innovation with Ottava, its revolutionary surgical robot.
The company's MedTech unit has announced plans to submit an application to the United States Food and Drug Administration (FDA) in the second half of 2024, with the goal of initiating clinical trials for this advanced system.
Ottava stands out for incorporating four artificial arms on a standard-sized operating table, offering unprecedented versatility in surgical procedures.
One of the most notable aspects of this device is its ability to reposition the patient without interrupting the ongoing operation, which promises to improve efficiency and safety in the operating room.
The news comes at a time when Intuitive Surgical has dominated the robotic surgery market with its well-known Da Vinci robot. However, Johnson & Johnson seeks to compete and stand out in this competitive medical space with Ottava. Additionally, Medtronic Plc is also working to enter the robotic surgery market with its own system, Hugo.
The race for supremacy in robotic surgery is more competitive than ever, and Ottava presents itself as a serious contender.
With the clinical trial application planned for the second half of 2024, Johnson & Johnson is taking firm steps toward the future of surgical medicine, opening new possibilities to improve the precision and efficacy of medical procedures.
Information from: Forbes.
Receive all industry news in our weekly newsletter Scientific Dialectics.